Use of Targeted Agents in Generalized Myasthenia Gravis

Key Takeaways

• FcRn and complement inhibitors are used in gMG patients unresponsive to traditional therapies, offering targeted treatment options.
• Long-term management of gMG with these inhibitors requires careful integration into treatment plans for refractory cases.
• Monitoring involves assessing clinical symptoms, antibody levels, and side effects to ensure therapeutic efficacy and safety.
• Tailored treatment strategies are crucial for patients with inadequate disease control on conventional therapies, optimizing outcomes.